The new gene therapies for sickle cell disease—including the gene-editing treatment Casgevy, based on research at Boston Children’s Hospital—have been game-changing for the patients who have received them. But Stuart Orkin, MD, the Boston Children’s hematologist whose work led the way to Casgevy, wants to go even further.
Medical Xpress – latest medical and health news stories
